U klikt door naar een site van derden.

GSK aanvaardt betreffende het gebruik van websites in beheer door derden, inclusief hun inhoud, geen enkele verantwoordelijkheid.

Verder

Ga terug

Product menu

NA

EXDENSUR: Ultra-long-lasting efficacy in severe uncontrolled CRSwNPa,1

Offer your patients an add-on treatment with only two administrations per year and an ultra-long duration of action.1

EXDENSUR may help reduce the need for future CRSwNP interventions.1

Are your patients at risk of CRSwNP recurrence?

EXDENSUR demonstrated a reduction in the need for rescue treatment, including systemic corticosteroids and surgery, versus placebo.1,4

Lachender Mann

Hypothetical Patient

  • CRSwNP
  • Comorbid Asthma (presence of T2 inflammation)
  • Polyp recurrence 11 months after surgery
  • Current NPS = 4
  • SNOT-22 score = 45
  • Previously showed good response to systemic corticosteroids
  • Blood eosinophils: 310 EOS/µL
  • Daily intranasal corticosteroids
  • Regular nasal irrigation

Help reduce the burden of repeated systemic corticosteroid use and surgery in patients with severe CRSwNP.1,4

Which CRSwNP Patients May Benefit from EXDENSUR?

EPOS/EUFOREA-Guideline:

According to the EPOS/EUFOREA guideline, at least 3 criteria should be met when prescribing biologics for patients with CRSwNP:2

EPOS/EUFOREA-Guideline EPOS/EUFOREA-Guideline


More about Exdensur

Teaser Wirkansatz

Mechanism of Action

  • Designed for ultra-long-lasting control of type 2 inflammation3,4
  • Efficient IL-5 blockade1,3
  • Prolonged serum half-lifeb,c,1

Learn more
Teaser Dosierung

Dosing

Only 2 injections per year for ultra-long-lasting efficacy.d,1

More about Dosing
Teaser Sicherheit

Safety

  • Safety profile comparable to placebo.1
  • 99% of patients continued treatment throughout the study.4–6

Learn more

  • Abbreviations

    CRSwNP = Chronic Rhinosinusitis with Nasal Polyps; EPOS = European Position Paper on Rhinosinusitis and Nasal Polyps; EUFOREA = European Forum for Research and Education in Allergy and Airway Diseases; IL = Interleukin; NPS = Nasal Polyp Score; OCS = Oral Corticosteroids; SNOT-22 = Sino-Nasal Outcome Test-22.

  • Footnotes

    a EXDENSUR (depemokimab) is indicated as add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.1

    b Compared with the serum half-life of mepolizumab and benralizumab (16–22 days and 15.5 days respectively).2,3

    c The YTE region is a modified part of an antibody that contributes to a longer duration in the body by slowing its degradation.1

    d One injection every 26 weeks.

  • References

    1. GlaxoSmithKline EXDENSUR(depemokimab). Summary of Product Characteristics(SmPC). 2026.
    2. Fokkens WJ, et al. Rhinology 2023;61(3):194–202.
    3. Singh D, Fuhr R, Bird NP, et al. A phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma. Br J Clin Pharmacol. 2022;88(2):702-712. Available at: https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15002.
    4. Gevaert P, Desrosiers M, Cornet M, et al. Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomized, double-blind, parallel trials. Lancet. 2025;405(10482):911-926. Available at: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00197-7/abstract.
    5. SWIFT-1 CSR (206713 CSR Report Body 02 SEP 2024)/p19/Table 3.
    6. SWIFT-2 CSR (213744 CSR Report Body 02 SEP 2024)/p19/Table 3.

PM-BE-DEPE-WCNT-260014 - September 2026